{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:32:57Z","timestamp":1786980777663,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10549-024-07450-3","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T13:02:12Z","timestamp":1722344532000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors"],"prefix":"10.1007","volume":"208","author":[{"given":"Sima","family":"Fansa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Ghusn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Tama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Nicolalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Anazco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy D.\u2019","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie S.","family":"Faubion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisandra L.","family":"Shufelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D.","family":"Hurtado Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"issue":"7","key":"7450_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2174\/1389557517666171101100902","volume":"18","author":"SP Avvaru","year":"2018","unstructured":"Avvaru SP et al (2018) Aromatase inhibitors evolution as potential class of drugs in the treatment of postmenopausal breast cancer women. Mini Rev Med Chem 18(7):609\u2013621","journal-title":"Mini Rev Med Chem"},{"issue":"3","key":"7450_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ecl.2011.05.009","volume":"40","author":"D Germain","year":"2011","unstructured":"Germain D (2011) Estrogen carcinogenesis in breast cancer. Endocrinol Metab Clin North Am 40(3):473\u2013484 (vii)","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"7450_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","volume":"94","author":"T Key","year":"2002","unstructured":"Key T et al (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606\u2013616","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"7450_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10549-010-0802-6","volume":"124","author":"HI Su","year":"2010","unstructured":"Su HI et al (2010) Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 124(1):205\u2013211","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"7450_CR5","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1200\/JCO.1996.14.7.2000","volume":"14","author":"A Buzdar","year":"1996","unstructured":"Buzdar A et al (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex study group. J Clin Oncol 14(7):2000\u20132011","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"7450_CR6","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.3816\/CBC.2000.s.004","volume":"1","author":"R Paridaens","year":"2000","unstructured":"Paridaens R et al (2000) Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer 1(Suppl 1):S19\u2013S21","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"7450_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1470-2045(18)30116-5","volume":"19","author":"S De Placido","year":"2018","unstructured":"De Placido S et al (2018) Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol 19(4):474\u2013485","journal-title":"Lancet Oncol"},{"issue":"1","key":"7450_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13668-013-0068-9","volume":"3","author":"M Azrad","year":"2014","unstructured":"Azrad M, Demark-Wahnefried W (2014) The association between adiposity and breast cancer recurrence and survival: a review of the recent literature. Curr Nutr Rep 3(1):9\u201315","journal-title":"Curr Nutr Rep"},{"issue":"21","key":"7450_CR9","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM et al (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143(21):e984\u2013e1010","journal-title":"Circulation"},{"key":"7450_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003921","author":"CE Ndumele","year":"2016","unstructured":"Ndumele CE et al (2016) Obesity and subtypes of incident cardiovascular disease. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.116.003921","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"7450_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/djn014","volume":"100","author":"JA Chapman","year":"2008","unstructured":"Chapman JA et al (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100(4):252\u2013260","journal-title":"J Natl Cancer Inst"},{"issue":"31","key":"7450_CR12","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2006.08.0499","volume":"25","author":"EO Hanrahan","year":"2007","unstructured":"Hanrahan EO et al (2007) Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 25(31):4952\u20134960","journal-title":"J Clin Oncol"},{"issue":"7","key":"7450_CR13","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/cncr.32648","volume":"126","author":"AM Afifi","year":"2020","unstructured":"Afifi AM et al (2020) Causes of death after breast cancer diagnosis: a US population-based analysis. Cancer 126(7):1559\u20131567","journal-title":"Cancer"},{"issue":"1","key":"7450_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12905-020-01002-9","volume":"20","author":"C Ee","year":"2020","unstructured":"Ee C et al (2020) Weight management barriers and facilitators after breast cancer in Australian women: a national survey. BMC Womens Health 20(1):140","journal-title":"BMC Womens Health"},{"issue":"3","key":"7450_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1210\/er.2012-1055","volume":"34","author":"F Mauvais-Jarvis","year":"2013","unstructured":"Mauvais-Jarvis F, Clegg DJ, Hevener AL (2013) The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 34(3):309\u2013338","journal-title":"Endocr Rev"},{"key":"7450_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/nu11071514","author":"P De Cicco","year":"2019","unstructured":"De Cicco P et al (2019) Nutrition and breast cancer: a literature review on prevention treatment and recurrence. Nutrients. https:\/\/doi.org\/10.3390\/nu11071514","journal-title":"Nutrients"},{"issue":"12","key":"7450_CR17","doi-asserted-by":"publisher","first-page":"djv275","DOI":"10.1093\/jnci\/djv275","volume":"107","author":"MC Playdon","year":"2015","unstructured":"Playdon MC et al (2015) Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst 107(12):djv275","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"7450_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1467-789X.2010.00805.x","volume":"12","author":"V Vance","year":"2011","unstructured":"Vance V et al (2011) Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 12(4):282\u2013294","journal-title":"Obes Rev"},{"issue":"4","key":"7450_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12282-022-01355-z","volume":"29","author":"Y Pang","year":"2022","unstructured":"Pang Y, Wei Y, Kartsonaki C (2022) Associations of adiposity and weight change with recurrence and survival in breast cancer patients: a systematic review and meta-analysis. Breast Cancer 29(4):575\u2013588","journal-title":"Breast Cancer"},{"issue":"3","key":"7450_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s10549-019-05501-8","volume":"179","author":"KA Nyrop","year":"2020","unstructured":"Nyrop KA et al (2020) Weight trajectories in women receiving systemic adjuvant therapy for breast cancer. Breast Cancer Res Treat 179(3):709\u2013720","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7450_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12885-015-1026-2","volume":"15","author":"D Vagenas","year":"2015","unstructured":"Vagenas D et al (2015) Weight and weight change following breast cancer: evidence from a prospective, population-based, breast cancer cohort study. BMC Cancer 15(1):28","journal-title":"BMC Cancer"},{"issue":"1","key":"7450_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1055-9965.EPI-16-0150","volume":"26","author":"EM Cespedes Feliciano","year":"2017","unstructured":"Cespedes Feliciano EM et al (2017) Postdiagnosis weight change and survival following a diagnosis of early-stage breast cancer. Cancer Epidemiol Biomark Prev 26(1):44\u201350","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"7450_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1080\/01635581.2011.539316","volume":"63","author":"X Chen","year":"2011","unstructured":"Chen X et al (2011) Weight change and its correlates among breast cancer survivors. Nutr Cancer 63(4):538\u2013548","journal-title":"Nutr Cancer"},{"key":"7450_CR24","doi-asserted-by":"publisher","first-page":"713700","DOI":"10.3389\/fendo.2021.713700","volume":"12","author":"T Hyder","year":"2021","unstructured":"Hyder T et al (2021) Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol (Lausanne) 12:713700","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"7450_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1012848","volume":"366","author":"JD Berry","year":"2012","unstructured":"Berry JD et al (2012) Lifetime risks of cardiovascular disease. N Engl J Med 366(4):321\u2013329","journal-title":"N Engl J Med"},{"issue":"11","key":"7450_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368(11):987\u2013998","journal-title":"N Engl J Med"},{"issue":"9935","key":"7450_CR27","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"P McGale","year":"2014","unstructured":"McGale P et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127\u20132135","journal-title":"Lancet"},{"issue":"5","key":"7450_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/jcpt.13598","volume":"47","author":"Q Yu","year":"2022","unstructured":"Yu Q et al (2022) Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: a systematic review and meta-analysis. J Clin Pharm Ther 47(5):575\u2013587","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"7450_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41574-020-0381-5","volume":"16","author":"F Magkos","year":"2020","unstructured":"Magkos F, Hjorth MF, Astrup A (2020) Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16(10):545\u2013555","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"7450_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","volume":"54","author":"KF Petersen","year":"2005","unstructured":"Petersen KF et al (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54(3):603\u2013608","journal-title":"Diabetes"},{"issue":"1","key":"7450_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat K et al (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51(1):121\u2013129","journal-title":"Hepatology"},{"issue":"3","key":"7450_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/HJH.0b013e3283418875","volume":"29","author":"NE Straznicky","year":"2011","unstructured":"Straznicky NE et al (2011) Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens 29(3):553\u2013564","journal-title":"J Hypertens"},{"issue":"5","key":"7450_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11912-019-0787-1","volume":"21","author":"K Lee","year":"2019","unstructured":"Lee K et al (2019) The impact of obesity on breast cancer diagnosis and treatment. Curr Oncol Rep 21(5):41","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"7450_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-009-0512-0","volume":"119","author":"E de Azambuja","year":"2010","unstructured":"de Azambuja E et al (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02\u201398 trial. Breast Cancer Res Treat 119(1):145\u2013153","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"7450_CR35","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.1993.11.11.2081","volume":"11","author":"AB Kornblith","year":"1993","unstructured":"Kornblith AB et al (1993) Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The cancer and Leukemia Group B. J Clin Oncol 11(11):2081\u20139","journal-title":"J Clin Oncol"},{"issue":"4","key":"7450_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.clbc.2017.01.006","volume":"17","author":"MC de Boer","year":"2017","unstructured":"de Boer MC et al (2017) The mechanisms and effects of physical activity on breast cancer. Clin Breast Cancer 17(4):272\u2013278","journal-title":"Clin Breast Cancer"},{"issue":"24","key":"7450_CR37","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/jnci\/djj494","volume":"98","author":"RT Chlebowski","year":"2006","unstructured":"Chlebowski RT et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the women\u2019s intervention nutrition study. J Natl Cancer Inst 98(24):1767\u20131776","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"7450_CR38","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s12032-010-9536-x","volume":"28","author":"EM Ibrahim","year":"2011","unstructured":"Ibrahim EM, Al-Homaidh A (2011) Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol 28(3):753\u2013765","journal-title":"Med Oncol"},{"issue":"24","key":"7450_CR39","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1200\/JCO.2007.15.9822","volume":"26","author":"ML Irwin","year":"2008","unstructured":"Irwin ML et al (2008) Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol 26(24):3958\u20133964","journal-title":"J Clin Oncol"},{"issue":"25 Suppl 2","key":"7450_CR40","first-page":"S102","volume":"129","author":"MD Jensen","year":"2014","unstructured":"Jensen MD et al (2014) 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129(25 Suppl 2):S102\u2013S138","journal-title":"Circulation"},{"issue":"1","key":"7450_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.mcna.2017.08.006","volume":"102","author":"DH Ryan","year":"2018","unstructured":"Ryan DH, Kahan S (2018) Guideline recommendations for obesity management. Med Clin North Am 102(1):49\u201363","journal-title":"Med Clin North Am"},{"issue":"10","key":"7450_CR42","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJM199503093321001","volume":"332","author":"RL Leibel","year":"1995","unstructured":"Leibel RL, Rosenbaum M, Hirsch J (1995) Changes in energy expenditure resulting from altered body weight. N Engl J Med 332(10):621\u2013628","journal-title":"N Engl J Med"},{"issue":"11","key":"7450_CR43","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1210\/jc.2009-2566","volume":"95","author":"AB Crujeiras","year":"2010","unstructured":"Crujeiras AB et al (2010) Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin Endocrinol Metab 95(11):5037\u20135044","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"7450_CR44","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/ijo.2015.59","volume":"39","author":"FL Greenway","year":"2015","unstructured":"Greenway FL (2015) Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond) 39(8):1188\u20131196","journal-title":"Int J Obes (Lond)"},{"issue":"6","key":"7450_CR45","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","volume":"38","author":"J Ard","year":"2021","unstructured":"Ard J et al (2021) Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther 38(6):2821\u20132839","journal-title":"Adv Ther"},{"issue":"1","key":"7450_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mcna.2017.08.010","volume":"102","author":"KH Saunders","year":"2018","unstructured":"Saunders KH et al (2018) Obesity pharmacotherapy. Med Clin North Am 102(1):135\u2013148","journal-title":"Med Clin North Am"},{"issue":"10321","key":"7450_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","volume":"399","author":"Q Shi","year":"2022","unstructured":"Shi Q et al (2022) Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 399(10321):259\u2013269","journal-title":"Lancet"},{"issue":"9","key":"7450_CR48","doi-asserted-by":"publisher","first-page":"e2231982","DOI":"10.1001\/jamanetworkopen.2022.31982","volume":"5","author":"W Ghusn","year":"2022","unstructured":"Ghusn W et al (2022) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open 5(9):e2231982","journal-title":"JAMA Netw Open"},{"issue":"2","key":"7450_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 327(2):138\u2013150","journal-title":"JAMA"},{"issue":"11","key":"7450_CR50","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA et al (2023) Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 29(11):2909\u20132918","journal-title":"Nat Med"},{"issue":"9774","key":"7450_CR51","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM et al (2011) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377(9774):1341\u20131352","journal-title":"Lancet"},{"issue":"3","key":"7450_CR52","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jpain.2012.11.010","volume":"14","author":"Q Shi","year":"2013","unstructured":"Shi Q et al (2013) Anastrozole-associated joint pain and other symptoms in patients with breast cancer. J Pain 14(3):290\u2013296","journal-title":"J Pain"},{"issue":"1","key":"7450_CR53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cam4.1911","volume":"8","author":"K Buch","year":"2019","unstructured":"Buch K et al (2019) Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-A systematic review. Cancer Med 8(1):238\u2013245","journal-title":"Cancer Med"},{"issue":"5","key":"7450_CR54","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.1986.4.5.678","volume":"4","author":"MT Knobf","year":"1986","unstructured":"Knobf MT (1986) Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol 4(5):678\u2013684","journal-title":"J Clin Oncol"},{"issue":"7","key":"7450_CR55","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ et al (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA 314(7):687\u2013699","journal-title":"JAMA"},{"issue":"10278","key":"7450_CR56","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M et al (2021) Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971\u2013984","journal-title":"Lancet"},{"issue":"4","key":"7450_CR57","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/oby.22430","volume":"27","author":"KH Lewis","year":"2019","unstructured":"Lewis KH et al (2019) Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity 27(4):591\u2013602","journal-title":"Obesity"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07450-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07450-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07450-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T13:02:18Z","timestamp":1730206938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07450-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7450"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07450-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MDHA is supported by NIH (K12-AR084222). AA is supported by NIH (K23-DK114460). AA is a stockholder in Gila Therapeutics, Phenomix Sciences; he served as a consultant for Rhythm Pharmaceuticals, General Mills, Currax, Nestle, Amgen, Structure, and Boehringer Ingelheim. There are no other disclosures. The other authors declare no conflicts of interest. CLS is supported by NIH (R01-HD106096).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}